[22] Calcific aortic stenosis, like osteoporosis, is a disease associated with aging and inflammation. [23] A therapeutic strategy designed to antagonize the effect of increased RANKL signaling upon tissue inflammation and mineralization, using the neutralizing monoclonal antibody denosumab, is safe and effective for patients with osteoporosis. [24] Thus, an approach with a similar mechanistic basis targeted at pathological dysregulation of mineralization in aortic valve tissue may offer opportunities for exploration of therapies for patients who are prone to develop aortic stenosis. The gene discussed is TNFSF11; the disease is osteoporosis.